The risk of malignancy and its incidence in early rheumatoid arthritis patients treated with biologic DMARDs
Abstract Background Treatment with disease-modifying anti-rheumatic drugs (DMARDs) has raised concerns about the risk of malignancies in rheumatoid arthritis (RA) patients. However, the association between biologic DMARDs (bDMARDs) and malignancy in previous reports remains controversial. Therefore...
Main Authors: | Soo-Kyung Cho, Jiyoung Lee, Minkyung Han, Sang-Cheol Bae, Yoon-Kyoung Sung |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-12-01
|
Series: | Arthritis Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13075-017-1482-y |
Similar Items
-
Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis
by: Mysler E, et al.
Published: (2021-06-01) -
Clinical evaluation of DMARDs and NSAIDs in cases of Rheumatoid arthritis in Chhattisgarh
by: Basant Kumar Maheshwari
Published: (2018-01-01) -
Iguratimod: Novel Molecular Insights and a New csDMARD for Rheumatoid Arthritis, from Japan to the World
by: Yuji Nozaki
Published: (2021-05-01) -
Predictors of good response to conventional synthetic DMARDs in early seronegative rheumatoid arthritis: data from the ESPOIR cohort
by: Cédric Lukas, et al.
Published: (2019-11-01) -
Statistical Information Included in Labeling for Disease-Modifying Anti-Rheumatic Drugs for Rheumatoid Arthritis
by: Hatch, Lashley
Published: (2012)